The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Post-progression survival after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor for advanced non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Yoshihito Kogure
No relevant relationships to disclose
Chiyoe Kitagawa
No relevant relationships to disclose
Masahide Oki
No relevant relationships to disclose
Hideo Saka
Consultant or Advisory Role - Lilly (U)
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical